{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-041096","form_type":"8-K","ticker":"PLUR","cik":"0001158780","company_name":"Pluri Inc.","filed_at":"2022-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.097365+00:00","generated_at":"2026-06-24T09:04:39.925957+00:00","sec_items":["5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Pluristem renamed Pluri Inc., ticker PLUR, pivots to multi-industry cell-based platform","bullets":["Name change from Pluristem Therapeutics Inc. to Pluri Inc. effective July 26, 2022.","Stock ticker symbol changes to 'PLUR' on Nasdaq Global Market.","CEO Yaky Yanay outlines strategic pivot to cell-based technology for food-tech, agri-tech, and biologics.","Commercialization strategy includes licensing and joint ventures ('Pluri focus units') with separate funding and management.","Continues medical research but expands into non-medical cell-based solutions via partnerships."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-041096","json":"https://secwatch.observer/filing/0001213900-22-041096.json","markdown":"https://secwatch.observer/filing/0001213900-22-041096.md","text":"https://secwatch.observer/filing/0001213900-22-041096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1158780/000121390022041096/0001213900-22-041096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1158780/000121390022041096/ea163272-8k_pluriinc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T09:04:39.925957+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}